Moderna's chief medical officer on its blockb...

Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Axios cofounder and CEO Jim VandeHei joins Axios Re:Cap senior producer Naomi Shavin to talk about what journalists got right a ...  Show more

Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022. Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major ...  Show more

Americans fortunate enough to receive vaccines right now, outside of clinical trials, are getting ones made by either Pfizer or Moderna. But newly released data from Novavax and Johnson & Johnson suggests that more vaccines could be on the way. Dan digs into the news and why it m ...  Show more

Promising signs in pandemic: vaccine progress, cases and hospitalizations down, deaths slow in new estimate; WH: 3-4 million doses of J&J vaccine to go out next week if FDA grants emergency use; Moderna testing vaccine boosters to combat South Africa variant; WH: J&J’s production ...  Show more

Moderna CEO Stephane Bancel talks about the Moderna vaccine, drug prices, and future of the company with Bloomberg's Paul Sweeny and Matt Miller. See omnystudio.com/listener for privacy information. 

It’s a dark time in the struggle with the coronavirus, particularly in the United States, where infections and hospitalizations have surged.

But amid the gloom comes some light: A trial by the drug maker Pfizer has returned preliminary results suggesting that its vaccine ...